why choose us

First received: July 06, 2023

Clinical Trial: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Locally Advanced Unresectable or Metastatic Esophageal Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.

Brief Summary: This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.

Read more